The SVIN-Trial-Just Another Brick in the Wall? [PDF]
J Clin Exp HepatolMehtani R.
europepmc +1 more source
Emerging Therapeutics for Primary Biliary Cholangitis. [PDF]
Korean J GastroenterolCho EJ.
europepmc +1 more source
Quick glance at 'metabolic dysfunction associated steatotic liver disease' therapeutics: Targets, trials, and trends. [PDF]
World J Gastrointest Pharmacol TherZacharia GS +4 more
europepmc +1 more source
The immunometabolic mechanisms and therapeutic targets of metabolic dysfunction-associated steatohepatitis. [PDF]
Front Med (Lausanne)Yu J, Peng Y.
europepmc +1 more source
Real time clinical efficacy and safety of saroglitazar in diabetic dyslipidemia [PDF]
, 2017 openaire +1 more source
Efficacy and safety of PPAR agonists in primary biliary cholangitis: a systematic review and meta-analysis of Randomized Controlled Trials. [PDF]
BMC GastroenterolSaeedian B +4 more
europepmc +1 more source
Cardioprotective Effects of SAR Through Attenuating Cardiac-Specific Markers, Inflammatory Markers, Oxidative Stress, and Anxiety in Rats Challenged with 5-Fluorouracil. [PDF]
J XenobiotRasheed RH, Aziz TA.
europepmc +1 more source
Diallyl trisulfide attenuates metabolic syndrome <i>via</i> integrated modulation of PCSK-9/LDL-R axis, redox homeostasis, and inflammatory cytokine networks in high-carbohydrate high-fat (HCHF) diet-fed rats. [PDF]
Front PharmacolAhmad P +8 more
europepmc +1 more source
PPAR-α activator pemafibrate lowered plasma insulin-like growth factor-1 level in a patient with acromegaly. [PDF]
Endocrinol Diabetes Metab Case RepYoshimichi G.
europepmc +1 more source
A Case of Diabetes With a Rare Variant of Familial Combined Hyperlipidemia With an Atypical Phenotype. [PDF]
CureusBhade K +3 more
europepmc +1 more source